Single-dose tioconazole compared with 3-day clotrimazole treatment in vulvovaginal candidiasis.

Treatment of vaginal candidiasis using a three-day course of Tioconazole: a preliminary report.

Oral fluconazole 150 mg single dose versus intra-vaginal clotrimazole treatment of acute vulvovaginal candidiasis.

OBJECTIVE To compare the safety and efficacy of fluconazole 150 mg single dose and intra-vaginal clotrimazole 200mg per day for six days in the treatment of the acute episode of vulvovaginal candidiasis (VVC). METHODS In a prospective study, 142 patients with acute clinical and mycological confirmed VVC were enrolled and divided randomly in two groups. 70 patients received intra-vaginal table...

Comparative Study of the Effectiveness of Oral Fluconazole and Intravaginal Clotrimazole in the Treatment of Vaginal Candidiasis

OBJECTIVE A study was carried out to compare 3 treatment regimens for vaginal candidiasis. METHODS A total of 150 women with clinical and mycological evidence of vaginal candidiasis were randomized to receive 50 mg of oral fluconazole daily for 6 days (50 women), a single oral 150 mg dose of fluconazole (50 women), or 100 mg of intravaginal clotrimazole daily for 6 days (50 women). They were ...

Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet.

The therapeutic efficacy of intermittent, monthly, postmenstrual prophylaxis with a single 500 mg clotrimazole vaginal tablet (n = 33) was compared with placebo tablets (n = 29) in 62 woman (age 28.1, SD 7.2 years) with recurrent vulvovaginal candidiasis. The number of episodes of acute vulvovaginal candidiasis experienced during the year prior to inclusion was 6.3, SD 1.9. The cumulative recur...

The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis.

OBJECTIVE To determine the comparative efficacy and cost benefit of prophylactic monthly (perimenstrual) clotrimazole, versus empiric self-treatment with the same agent at the onset of symptoms in recurrent vulvovaginal candidiasis. DESIGN Prospective, randomised, open cross-over study of women with proven recurrent vulvovaginal candidiasis. Clinical and microbiological assessments were done ...